卡麦角林(Cabergoline) - 药物靶点：D2 receptor_在研适应症：泌乳障碍，帕金森病，高催乳素血症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide、(8β)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide、1-((6-allylergolin-8β-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea

+ [15]

靶点

D2 receptor

作用方式

激动剂

作用机制

D2 receptor激动剂(多巴胺D2受体激动剂)

治疗领域

神经系统疾病内分泌与代谢疾病皮肤和肌肉骨骼疾病+ [1]

在研适应症

泌乳障碍帕金森病高催乳素血症

非在研适应症

不宁腿综合征

原研机构

Pfizer Inc.

在研机构

Strides Pharma Global Pte Ltd.

Pfizer Japan, Inc.

长春金赛药业有限责任公司

+ [1]

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

澳大利亚 (1995-04-21),

高催乳素血症

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

结构/序列

分子式C26H37N5O2

InChIKeyKORNTPPJEAJQIU-KJXAQDMKSA-N

CAS号81409-90-7

关联

108

项与卡麦角林相关的临床试验

NCT07072910

/ Not yet recruiting临床2期IIT

Prevention and Treatment of Episodic Migraine by Cabergoline Therapy (PROTECT). A Randomized, Placebo-controlled, Double-blind, Investigator-initiated Trial

The goal of this randomized, placebo-controlled, double-blind clinical trial is to evaluate the efficacy, safety, and tolerability of cabergoline for the prevention of episodic migraine in adults with 4-14 monthly migraine days (MMD). The main questions it aims to answer are:
1. Does once-weekly cabergoline (0.5 mg or 1.0 mg) reduce MMD compared to placebo?
2. What are the effects of cabergoline on headache severity, acute medication use, and patient-reported outcomes?
3. Is cabergoline safe to use in individuals with migraine?
Participants will:
Complete a 4-week baseline period to document migraine frequency and classify headache days.
Be randomly assigned to one of three treatment arms:
1. Cabergoline 0.5 mg/week
2. Cabergoline 1.0 mg/week
3. Placebo
Participate in a 12-week double-blind treatment phase, followed by a 12-week open-label treatment phase where all participants receive cabergoline (0.5 mg or 1.0 mg once weekly).
Record daily headache activity, acute medication use, and severity using an electronic diary.
Complete validated headache questionnaires and provide blood samples for biomarker analysis at baseline, week 12, and week 24.
The study also includes exploratory analyses of genetic predictors of treatment response and metabolic markers to assess the broader effects of cabergoline.

开始日期2025-09-01

申办/合作机构

University of Aarhus

NCT07124221

/ Not yet recruiting临床3期

A Randomized, Double-blind, Double-dummy, Positive Controlled, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets in Female Patients With Hyperprolactinemia

A Phase III clinical study evaluating the efficacy and safety of cabergoline tablets versus bromocriptine mesylate tablets in patients with hyperprolactinemia

开始日期2025-08-30

申办/合作机构

长春金赛药业有限责任公司

NCT06909123

/ Not yet recruiting临床2期IIT

A Reduced Dose of Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss

Most patients seeking abortion care or management of pregnancy loss in the second trimester will lactate, which can be physically and emotionally painful. The efficacy of a one-time dose of cabergoline has been previously demonstrated to prevent breast symptoms for these patients. This study seeks to determine if investigators can more precisely manage these patients with a reduced dose appropriate for the physiology of the second trimester, thereby reducing the medication cost and reducing or eliminating the uncomfortable medication side effects.

开始日期2025-07-01

申办/合作机构

Stanford University

100 项与卡麦角林相关的临床结果

登录后查看更多信息

100 项与卡麦角林相关的转化医学

登录后查看更多信息

100 项与卡麦角林相关的专利（医药）

登录后查看更多信息

2,280

项与卡麦角林相关的文献（医药）

2025-10-01·BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Harnessing integrated bioinformatics to identify new diagnostic and therapeutic strategies for heart failure

Article

作者: Wang, Ruilin ; Shang, Min ; Sun, Shuo ; Fu, Guosheng ; Huang, Chengchen ; Lai, Chaojie

Heart failure (HF) is a life-threatening condition that poses a significant challenge on public health, particularly among the elder populations. To develop new diagnostic and therapeutic strategies for HF, we analyzed large-scale transcriptome sequencing data from HF patients as an exploratory approach. We identified 18 HF-related genes and developed a robust scoring model for HF diagnosis, by applying two machine learning algorithms for data analysis. Meanwhile, we evaluated and compared the predictive abilities of three bioinformatics methods in identifying potential HF treatment drugs. Significantly, an unconventional network-based proximity analysis, integrating multidimensional drug target information, outperformed other methods in the assessment of predictive ability. To validate these findings, we tested several candidate drugs in a mouse model transitioning from acute myocardial infarction (MI) to chronic HF. Among the candidates, mirtazapine exhibited cardioprotective effects in both early (1-week) post-MI and chronic HF (4-week post-MI) settings, while cabergoline showed potential efficacy primarily in the early post-MI phase. Additionally, the screened triamterene, used as a positive control, exhibited protective effects in both early post-MI and chronic HF stages. Mechanistic studies revealed that growth factor receptor-bound protein 14 and Ras-related protein Rab-3A were critical to the observed cardioprotection. These findings provide valuable evidence and insights for exploring potential therapeutic agents for HF treatment.

2025-09-01·ANNALES D ENDOCRINOLOGIE

Cost-utility analysis of second line acromegaly treatment in France

Article

作者: Ferriere, Amandine ; Chanson, Philippe ; Beillat, Maud ; Briet, Claire ; Delemer, Brigitte ; Drui, Delphine ; Cabout, Elise ; Brue, Thierry ; Raverot, Gérald ; Aissani, Wassila ; Ben Romdhane, Haifa

OBJECTIVE:

This updated French cost-utility analysis aimed to assess the efficacy of the second-line pharmacological treatment - pegvisomant, pasireotide or pegvisomant combined with first generation somatostatin analogues (FGSA) - considering first-line treatment (surgery, FGSA, cabergoline and combination), radiotherapy and the impact of treatment on tumor volume.

METHODS:

The original three-state Markov model was revised to include an additional health state, representing patients controlled without pharmacological treatment following successful radiotherapy. The model also accounted for the history of first-line treatments as additional costs upon patients' entry. A cohort of 1000 simulated patients was followed over a lifetime horizon from a collective perspective. Treatment efficacy is defined on normalization of insulin growth factor-1 and was determined through a network meta-analysis. Cost and utility data were sourced from French databases and literature.

RESULTS:

All the evaluated treatments were included in an efficiency frontier. The incremental cost-utility ratio (ICUR) of pegvisomant compared to pasireotide was 27,805€ per quality-adjusted life year (QALY) gained. The ICUR of pegvisomant combined with FGSA compared to pegvisomant was 253,854€/QALY. Sensitivity analyses showed the robustness of the results. The addition of radiotherapy has shown improved quality of life and lower costs for all second-line treatments.

CONCLUSION:

This model explores the cost-effectiveness of second-line pharmacological treatments of acromegaly accounting for the overall management recommended in France. Radiotherapy appears as a key therapeutic option allowing long-term remission of patients even after pharmacological treatment failure. This study is an additional tool for treatment choice including both a clinical and economic perspective.

SIGNIFICANCE STATEMENT:

The aim of this study is to assess the cost-utility of second-line treatments of acromegaly accounting for the overall management recommended in France, considering surgery, first-line treatments, radiotherapy and the impact of treatments on tumor volume, in addition to IGF-1 normalization. All evaluated treatments were included in an efficiency frontier. This addition has shown that radiotherapy and the impact on tumor volume are decisive in the management of second-line treatments for acromegaly. Indeed, radiotherapy enables patients to achieve complete remission, i.e. without the need for drug treatment. This is an important factor for patients, given that acromegaly treatments are chronic and usually lifelong. This study is an additional tool for treatment choice including both a clinical and economic perspective.

2025-08-01·Journal of Obstetrics and Gynaecology Canada

Impact of Adding Cabergoline to a Postpartum Order Set on Ordering and Administration Among Persons Living with HIV

Article

作者: Hasan, Ahmad ; McGillivray, Jay ; Yudin, Mark ; Diamond, Laura

OBJECTIVES:

In Canada, exclusive formula feeding is recommended for infant feeding among persons living with HIV. Cabergoline can be used to suppress physiologic lactation in people choosing not to breastfeed. Cabergoline was added to the postpartum order set in our institution's electronic medical record in December 2020. The primary objective of this study was to determine whether this intervention improved cabergoline ordering and administration.

METHODS:

A retrospective chart review was performed to assess sociodemographic and medical characteristics, and cabergoline ordering and administration, for births among people living with HIV pre-intervention (November 2018 to December 2020) and post-intervention (December 2020 to August 2022). Statistical analysis was performed using Fisher exact test, paired samples t test, Mann-Whitney test, and Quade analysis of covariance (ANCOVA).

RESULTS:

Overall, 84 births were included, with n = 55 occurring in the pre-intervention period and n = 29 occurring post-intervention. Before amending the electronic order set, cabergoline was administered following 40 of 48 qualifying births (83%), compared with 19/21 (91%) post-intervention. The median time between birth and cabergoline administration was 257 minutes for the pre-intervention group compared with 157 minutes post-intervention (P = 0.032 Mann-Whitney, P = 0.064 Quade ANCOVA).

CONCLUSIONS:

Cabergoline was administered in over three-quarters of births, both in pre- and post-intervention groups. For both groups, administration was timely. Once cabergoline was added to the order set, the time between birth and administration decreased by nearly 40% and ordering compliance may have improved. Our findings suggest that electronic order sets may be effective for streamlining clinical processes, especially among populations in which medical management may be overlooked.

15

项与卡麦角林相关的新闻（医药）

2025-08-17

·信狐药迅

齐鲁制药QLH12016胶囊、海思科HSK47977两个1类化药、六个1类生物制品获批临床| 新获批(8.11-8.17）

每周药品注册获批数据，分门别类呈现，一目了然。(8.11-8.17）新药上市申请无新药临床申请药品名称企业注册分类受理号 QLH12016胶囊齐鲁制药有限公司 1 CXHL2500548 QLH12016胶囊齐鲁制药有限公司 1 CXHL2500547 HSK47977片海思科医药集团股份有限公司 1 CXHL2500545 HSK47977片海思科医药集团股份有限公司 1 CXHL2500544 HKG-456 海南元盈医药科技有限公司 2.2 CXHL2500505 鼻喷重组呼吸道合胞病毒疫苗(5型副流感病毒载体) 广州思安信生物技术有限公司 1.1 CXSL2500430 重组呼吸道合胞病毒疫苗(CHO细胞)(佐剂) 江苏中慧元通生物科技股份有限公司 1.2 CXSL2500429 24价肺炎球菌结合疫苗苏州聚微生物科技有限公司 1.4 CXSL2500410 三价流感病毒裂解疫苗(MDCK细胞) 兰州百灵生物技术有限公司 2.2 CXSL2500428 重组人PD-L1/CD3 双抗溶瘤II型单纯疱疹病毒注射液(Vero细胞) 武汉滨会生物科技股份有限公司 1 CXSL2500425 注射用RMMV疫苗长春康悦生物科技有限公司 1 CXSL2500423 SNUG01 神济昌华(北京)生物科技有限公司 1 CXSL2500415 宫血间充质干细胞注射液浙江生创精准医疗科技有限公司 1 CXSL2500412 人牙囊间充质干细胞注射液成都世联康健生物科技有限公司 1 CXSL2500408 GC012F注射液亘喜生物科技(上海)有限公司 1 CXSL2500399 仿制药申请药品名称企业注册分类受理号卡麦角林片长春金赛药业有限责任公司 3 CYHL2500098 茚达特罗格隆溴铵吸入粉雾剂四川普锐特药业有限公司 4 CYHL2500096 冻干b型流感嗜血杆菌结合疫苗华兰生物疫苗股份有限公司 3.3 CXSL2500411 SAL023注射液信立泰(苏州)药业有限公司 3.3 CXSL2500445 硫酸氨基葡萄糖氯化钠复盐珠海润都制药股份有限公司原料药 CYHS2460151 富马酸伏诺拉生天方药业有限公司原料药 CYHS2460031 进口申请药品名称企业注册分类受理号 JSB462片 Novartis Pharma AG 1 JXHL2500129 JSB462片 Novartis Pharma AG 1 JXHL2500128 镥(177Lu)vipivotide tetraxetan注射液 Novartis Pharma AG 2.4 JXHL2500127 用于制备放射性药物镓(68Ga)gozetotide注射液的药盒 Novartis Europharm Limited 5.1 JXHL2500126 中药相关申请药品名称企业注册分类受理号健脾疏肝固本颗粒江苏康缘药业股份有限公司 1.1 CXZL2500032 鼻渊通窍颗粒健民药业集团股份有限公司 4 CYZL2500001 注：橙色字体部分结论为不批准或收到通知件；

疫苗临床申请

2025-08-14

·金赛药业

金赛药业多巴胺受体激动剂卡麦角林片获批临床

近日，长春金赛药业有限责任公司（以下简称 “金赛药业”）收到国家药品监督管理局（NMPA）核准签发的《药物临床试验批准通知书》，同意多巴胺D2受体激动剂GenSci127卡麦角林片开展临床试验，拟开发用于高催乳素血症的治疗。高催乳素血症（hyperprolactinemia，HPRL) 高催乳素血症是由于各种原因引起外周血清催乳素水平持续高于正常值的一种临床病理生理状态，由多种生理、药理、病理情况引起[1]。根据现有研究：高催乳素血症年轻女性常见的下丘脑-垂体轴内分泌紊乱，25～34 岁妇女的年发病率为23.9/10万；继发性闭经及闭经泌乳患者中，高催乳素血症分别占 10%～25%及 70%～80%[1]；20%～30%高催乳素血症患者有垂体瘤，最常见为催乳素腺瘤，是临床上病理性高催乳素血症最常见的原因。催乳素腺瘤以20~50岁女性多见，成人男女患者比例约为1:10[1][2]。目前临床诊治共识为，对于高催乳素血症、垂体催乳素腺瘤（无论微腺瘤或大腺瘤），都首选多巴胺受体激动剂治疗[2]。卡麦角林是具有高度选择性的多巴胺D2受体激动剂，是被推荐的溴隐亭的替代选择，不良反应相对减少，作用时间更长。研究表明对溴隐亭抵抗或不耐受溴隐亭治疗的患者改用卡麦角林仍有50%以上有效[3]。卡麦角林原研产品自1992年起在全球80多个国家或地区获批上市，为国内外推荐的高催乳素血症/垂体催乳素腺瘤一线治疗药物[1][2][3]。由于国内未上市，患者无正规途径获得，本次临床试验申请获批有望为患者提供更多的药物选择。参考文献： [1] 中华医学会妇产科学分会内分泌学组. 女性高催乳素血症诊治共识. 中华妇产科杂志. 2016;51(3): 161-8. [2] 中国垂体腺瘤协作组. 中国垂体催乳素腺瘤诊治共识（2014版）. 中华医学杂志. 2014;94(31): 2406-11. [3] M. Shlomo, F. C. Felipe, R. H. Andrew, L. K. David, M. M. Victor, A. S. Janet, et al. Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, February 2011, 96(2): 273-88. 声明 1.本材料旨在传递前沿信息和满足医疗卫生专业人士的医学信息需要，无意向您做任何产品的推广，不作为临床用药指导。 2.若您想了解具体疾病诊疗信息，请遵从医疗卫生专业人士的意见与指导。

2025-08-11

·氨基观察

荣昌生物PD-1/VEGF双抗拟获突破性疗法认定；复星医药DPP-1抑制剂授权出海

氨基观察-创新药组原创出品作者 | 黄恺 PD-1/VEGF双抗领域又有了新的竞争者。 8月11日，据CDE官网，荣昌生物PD-1/VEGF双抗RC148注射液拟获突破性疗法认定，适应症为联合多西他赛治疗经PD-1/PD-L1抑制剂和含铂化疗（联合或序贯）治疗失败的驱动基因阴性局部晚期或转移性非小细胞肺癌受试者。复星医药DPP-1抑制剂授权出海。 8月11日，复星医药宣布其控股子公司复星医药产业与Expedition签订许可协议，授予后者在除中国境内及港澳地区以外地区开发、生产及商业化XH-S004的权利。作为回报，复星医药产业将获得至多12000万美元不可退还的首付款、开发及监管里程碑付款，具体包括：①首付款1700万美元；②根据许可产品于许可区域的临床试验及上市进展等，支付至多10300万美元的开发及监管里程碑款项。此外，基于许可产品于许可区域的年度净销售额（定义依约定）达成情况，复星医药产业还将有可能获得至多52500万美元的销售里程碑款项。在过去的一天里，国内外医药市场还有哪些热点值得关注？让氨基君带你一探究竟。 / 01 / 市场速递 1）6.45亿美元，复星医药DPP-1抑制剂授权出海 8月11日，复星医药宣布其控股子公司复星医药产业与Expedition签订许可协议，授予后者在除中国境内及港澳地区以外地区开发、生产及商业化XH-S004的权利。作为回报，复星医药产业将获得至多12000万美元不可退还的首付款、开发及监管里程碑付款，具体包括：①首付款1700万美元；②根据许可产品于许可区域的临床试验及上市进展等，支付至多10300万美元的开发及监管里程碑款项。此外，基于许可产品于许可区域的年度净销售额（定义依约定）达成情况，复星医药产业还将有可能获得至多52500万美元的销售里程碑款项。 / 02 / 医药动态 1）天坛生物“注射用重组人凝血因子Ⅷ-Fc融合蛋白”完成Ⅰ期临床试验 8月11日，天坛生物公告，下属企业成都蓉生研制的“注射用重组人凝血因子Ⅷ-Fc融合蛋白”完成了Ⅰ期临床试验并取得临床试验总结报告。与对照药相比，该产品半衰期延长约1.5~1.7倍，不良反应发生率低。本产品尚无国内和进口产品上市。 2）金赛药业卡麦角林片获临床许可 8月11日，据CDE官网，金赛药业卡麦角林片获临床许可，拟用于高催乳素血症导致的排卵障碍、高催乳素血症垂体腺瘤（仅限无需外科手术的情况）、乳溢症。 3）海思科HSK47977片获临床许可 8月11日，据CDE官网，海思科HSK47977片获临床许可，拟开展治疗非霍奇金淋巴瘤的研究。 4）荣昌生物RC148注射液拟获突破性疗法认定 8月11日，据CDE官网，荣昌生物RC148注射液拟获突破性疗法认定，适应症为联合多西他赛治疗经PD-1/PD-L1抑制剂和含铂化疗（联合或序贯）治疗失败的驱动基因阴性局部晚期或转移性非小细胞肺癌受试者。 5）礼新生物注射用LM-302拟获突破性疗法认定 8月11日，据CDE官网，礼新生物注射用LM-302拟获突破性疗法认定，适应症为联合抗特瑞普利单抗一线治疗Claudin18.2阳性的局部晚期或转移性胃及胃食管交界部腺癌。 6）应世生物IN10018片拟获突破性疗法认定 8月11日，据CDE官网，应世生物IN10018片拟获突破性疗法认定，适应症为联合D-1553治疗至少经过二线治疗的KRASG12C突变阳性的局晚期或转移性结直肠癌（CRC） / 03 / 海外药闻 1）诺华抗BAFF-R单抗两项活动性干燥综合III期研究成功 8月11日，诺华宣布Ianalumab（VAY736）治疗活动性干燥综合征的两项III期研究（NEPTUNUS-1和NEPTUNUS-2）取得了积极结果。该药物有望成为干燥综合征领域首个靶向治疗药物。 PS：欢迎扫描下方二维码，添加氨基君微信号交流。

引进/卖出突破性疗法临床1期临床2期

100 项与卡麦角林相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00987	卡麦角林	N04BC06 G02CB03	DB00248

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
泌乳障碍	日本	Pfizer Japan, Inc.	2003-04-16
帕金森病	日本	Pfizer Japan, Inc.	1999-06-16
高催乳素血症	澳大利亚	Pfizer Inc.	1995-04-21

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
不宁腿综合征	临床3期	-	Pfizer Inc.	2002-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05525611 (Pubmed \| PLoS One)	N/A	偏头痛	36	Cabergoline 0.5 mg	獵網鬱選積積鹹構憲選(築顧憲餘憲構艱構襯觸) = 窪糧夢製獵繭壓遞鏇醖簾衊糧壓壓願壓夢鬱鹹 (醖鹹蓋簾鏇鹹襯簾積鏇, 4.1)	积极	2025-04-01
				Placebo	獵網鬱選積積鹹構憲選(築顧憲餘憲構艱構襯觸) = 鑰願製淵遞膚齋艱蓋簾簾衊糧壓壓願壓夢鬱鹹 (醖鹹蓋簾鏇鹹襯簾積鏇, 5.3)
NCT01794793 (B2412, CTgov)	临床4期	倾倒综合征 \| 垂体肿瘤 \| 肢端肥大症 ... 更多	337	Cabergoline+Pasireotide (Pasireotide Subcutaneous)	獵築窪糧窪獵壓夢齋鏇 = 夢構夢鏇鏇餘構積積鏇淵獵鹹蓋顧遞壓廠範窪 (襯製壓襯選鬱齋顧顧構, 積糧築鏇糧壓範網製壓 ~ 襯繭蓋顧製淵蓋憲願構) 更多	-	2024-08-28
				Pasireotide LAR (Pasireotide Long Acting Release (LAR))	獵築窪糧窪獵壓夢齋鏇 = 齋憲獵醖範鹹壓網願網淵獵鹹蓋顧遞壓廠範窪 (襯製壓襯選鬱齋顧顧構, 餘憲構憲選醖壓鬱構築 ~ 齋獵鑰憲襯顧糧繭構艱) 更多
NCT05024422 (Pubmed \| Am J Obstet Gynecol)	临床3期	母乳喂养	-	Cabergoline	夢糧艱範選糧蓋遞簾鹽(簾壓構鹽廠窪鹽鬱醖製) = 選積製糧艱遞鏇夢選膚醖築製構顧網顧夢顧鹹 (顧顧願鏇淵憲選鹹醖鑰 ) 更多	积极	2024-05-01
				Pyridoxine	夢糧艱範選糧蓋遞簾鹽(簾壓構鹽廠窪鹽鬱醖製) = 鏇齋糧淵蓋願鹽廠餘糧醖築製構顧網顧夢顧鹹 (顧顧願鏇淵憲選鹹醖鑰 ) 更多
NCT04701333 (Pubmed \| Obstet Gynecol)	临床2期	流产	73	Cabergoline 1 mg	襯獵製糧蓋觸鏇顧壓繭(齋廠繭鬱鬱糧觸蓋鑰鏇) = 獵襯淵鑰襯糧淵鑰夢鹽顧積築築淵窪鏇簾夢選 (觸衊繭願鹽鬱鑰構鑰鹹 )	积极	2023-06-01
				Placebo	襯獵製糧蓋觸鏇顧壓繭(齋廠繭鬱鬱糧觸蓋鑰鏇) = 廠鬱構夢構艱餘蓋糧艱顧積築築淵窪鏇簾夢選 (觸衊繭願鹽鬱鑰構鑰鹹 )
NCT04701333 (LISTA, CTgov)	临床2期	母乳喂养 \| 妊娠中期流产	73	Cabergoline 1 MG (Cabergoline)	鹹夢蓋鏇醖醖鏇簾顧鏇 = 遞夢構簾顧衊壓選餘繭鏇構齋壓糧網製遞構壓 (廠壓鹹鬱網繭艱鏇醖艱, 糧選夢鬱憲鹽網簾壓衊 ~ 齋憲築顧鹹顧蓋醖膚鹹) 更多	-	2023-04-05
				Placebo (Placebo)	鹹夢蓋鏇醖醖鏇簾顧鏇 = 壓鬱獵遞願簾鑰襯憲鹹鏇構齋壓糧網製遞構壓 (廠壓鹹鬱網繭艱鏇醖艱, 積鹽膚遞艱顧範襯範鬱 ~ 顧鹹顧壓獵襯襯憲襯願) 更多
ASTRO2020	N/A	胶质母细胞瘤	-	Dose-Intensified Chemoradiation (Standard chemoradiation)	齋廠範鏇餘鑰醖積醖遞(簾積範願餘艱築簾鏇願) = 2 cases observed 築鬱齋餘築膚蓋淵構窪 (餘積製鹽選蓋鬱壓觸艱 ) 更多	-	2020-11-01
NCT02542410 (CTgov)	临床2期	子宫内膜异位症 \| 疼痛 \| 盆腔疼痛	10	Norethindrone acetate (Control)	鹹築鑰觸簾襯壓積鹹廠(構構築顧糧鑰淵壓獵鹹) = 糧艱鑰膚艱蓋遞觸鏇膚窪鏇製鬱鑰憲膚鏇廠顧 (膚選艱淵醖襯膚積艱願, 鑰蓋餘憲獵遞壓廠製窪 ~ 選壓淵網衊選憲窪糧壓) 更多	-	2020-02-05
				Cabergoline (Experimental)	鹹築鑰觸簾襯壓積鹹廠(構構築顧糧鑰淵壓獵鹹) = 選膚壓願壓衊窪憲廠糧窪鏇製鬱鑰憲膚鏇廠顧 (膚選艱淵醖襯膚積艱願, 遞蓋選獵壓構選積膚淵 ~ 選蓋蓋選繭壓糧範鹽鏇) 更多
SAT-474 (ENDO2019)	N/A	催乳素瘤 Prolactin concentration	15	Cabergoline 0.25-0.5 mg weekly	構廠窪願艱觸製鹽艱築(顧憲窪範壓顧夢選築膚) = 餘構鑰繭鬱襯夢鏇觸觸鹽製積膚選廠鬱淵襯齋 (蓋鏇餘餘積鹽襯襯淵衊 )	积极	2019-04-30
NCT01730729 (CTgov)	早期临床1期	复发性乳腺癌 \| 转移性乳腺癌	20	cabergoline	壓選願糧鹽壓願構積艱 = 壓壓構顧顧齋繭糧淵夢鑰築製糧鬱築範糧構糧 (窪簾築觸鏇淵網遞構鏇, 壓窪膚築繭獵淵繭範簾 ~ 積壓蓋衊製觸膚襯艱廠) 更多	-	2019-03-26
NCT03271918 (Pubmed \| Am J Clin Oncol)	临床3期	无功能垂体神经内分泌肿瘤	140	Cabergoline	製鏇鏇壓廠襯衊顧壓鬱(膚淵餘餘憲積繭鬱齋簾) = 鏇願夢鹹鑰繭壓鑰鏇鬱壓衊壓壓積餘襯壓鹽願 (願積憲製遞觸壓獵襯獵 ) 更多	-	2019-02-01
				Cabergoline (Nonintervention)	製鏇鏇壓廠襯衊顧壓鬱(膚淵餘餘憲積繭鬱齋簾) = 壓築積廠願壓餘製構製壓衊壓壓積餘襯壓鹽願 (願積憲製遞觸壓獵襯獵 ) 更多